(Q33871474)

2 July 2019

review article

1 reference

title

Orlistat, a new lipase inhibitor for the management of obesity (English)

1 reference

2 July 2019

triacylglycerol lipase inhibitor

main subject

obesity

0 references

1 reference

2

1 reference

PubMed publication ID

29 July 2017

A M Heck

1

1 reference

2 July 2019

K A Calis

series ordinal

3

1 reference

2 July 2019

language of work or name

English

0 references

publication date

1 March 2000

1 reference

2 July 2019

published in

Pharmacotherapy

1 reference

2 July 2019

volume

20

1 reference

2 July 2019

issue

3

1 reference

2 July 2019

page(s)

270-279

1 reference

2 July 2019

Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994).

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.270.34882

Actual causes of death in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.270.34882

New approaches in the pharmacological treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.270.34882

Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.270.34882

Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.270.34882

First clinical studies with orlistat: a short review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.270.34882

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.270.34882

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.270.34882

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.270.34882

The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.270.34882

Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.270.34882

Treatment with orlistat reduces cardiovascular risk in obese patients

21 January 2018

1 reference

12 December 2020

The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

1 reference

12 December 2020

1 reference

12 December 2020

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

12 December 2020

Lack of interaction between orlistat and oral contraceptives

1 reference

12 December 2020

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study

1 reference

12 December 2020

Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers

1 reference

12 December 2020

Is blockade of pancreatic lipase the answer?

1 reference

12 December 2020

Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study

1 reference

12 December 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers

1 reference

12 December 2020

Orlistat and weight loss

1 reference

12 December 2020

The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers

1 reference

12 December 2020

Medical hazards of obesity

1 reference

12 December 2020

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers

1 reference

12 December 2020

Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers

1 reference

12 December 2020

Current estimates of the economic cost of obesity in the United States

1 reference

12 December 2020

Quantitative determination of Orlistat (tetrahydrolipostatin, Ro 18-0647) in human plasma by high-performance liquid chromatography coupled with ion spray tandem mass spectrometry

1 reference

12 December 2020

1 reference

12 December 2020

A one-year trial to assess the value of orlistat in the management of obesity

1 reference

12 December 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers

1 reference

12 December 2020

The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia

1 reference

12 December 2020

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

1 reference

12 December 2020

The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase

1 reference

12 December 2020

Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin

1 reference

12 December 2020

Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin

1 reference

12 December 2020

United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years

1 reference

12 December 2020

Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients

1 reference

12 December 2020

The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers

1 reference

12 December 2020

Beneficial health effects of modest weight loss

1 reference

12 December 2020

The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers

1 reference

12 December 2020

Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin)

1 reference

12 December 2020

Inactivation of pancreatic and gastric lipases by tetrahydrolipstatin and alkyl-dithio-5-(2-nitrobenzoic acid). A kinetic study with 1,2-didecanoyl-sn-glycerol monolayers

1 reference

12 December 2020

10.1592/PHCO.20.4.270.34882

Identifiers

DOI

1 reference

2 July 2019

PMC publication ID

6145169

1 reference

2 July 2019

PubMed publication ID

10730683

1 reference

2 July 2019